Research Gate

Teaching & Academic Contributions

• PharmD Teaching: 
  • Pharmaceutics I
  • Pharmacy Lab I
• Graduate Teaching: 
  • Physical Pharmacy
  • Pharmaceutical Unit Operations
  • GMPs for 21^st Century Certificate
  • Advising: 3 doctoral students (TUSP)

Research Focus & Activities

Dr. Lebo’s research interests are in Regulatory Affairs with key projects including direct-to-consumer genetic testing and orphan drug approvals. Dr. Lebo’s work also focuses on mechanisms of orphan drug approvals, clinical study sizes, and development timelines for the efficacy of research programs. His interests further include the evaluation of topical, transdermal, and trans-ungual formulations with an emphasis on solubility enhancement.

Collaboration Opportunities:

Dr. Lebo frequently participates in collaborations involving clinical supplies for multi-center NIH and DOD sponsored clinical trials. Additionally, he is currently training students in CGMP and is developing a continuous manufacturing program in QA/QA.

Key Interests: regulatory filing mechanisms; quality systems; quality-by-design approaches

Select Publications

• Jiang S, Lebo D, Schultz T. Public Perspectives on Direct-to-Consumer Testing Oversight. Ther Innov Regul Sci. 2024 Nov;58(6):1027-1030.
• Friedman R, Lebo D, Liberti L, Raju GK. ICH Q9: Attaining a Quality-Business Synergy through Quality Risk Management, ROI Analysis, and Highly Capable Facilities, Pharmaceutical Technology, 2024 eBook;1:30-45

• Nattkemper LA, Zhi K, Romero KE, Shah SM, Ju T, Fourzali K, Golpanian RS, MacQuhae F, Chan YH, Lebo DB, Yosipovitch G. Antipruritic Effect of Topical Acetaminophen Gel in Histaminergic and Non-histaminergic Itch Provocation: A Double-blind, Vehicle-controlled Pilot Study. Acta Derm Venereol. 2022 Jan 31;102:adv00640.

Current CGMP Studies

• Metformin to Attenuate ProgressiVe Respiratory deCline in IPF (MAVRIC-IPF), F. Martinez (PI), UNC, DCC, Dept of Defense (Jan. 2025 – Dec. 2029).
• Metformin IN Asthma for overweight and obese individuals (MINA), D. Wu (PI), Baylor, Johns Hopkins DCC, National Heart Lung Blood Health Institute, NHLBI (July 2023 – June 2026). 
• Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients, H. Chapman (PI), SABER (Michigan), DCC, National Heart Lung Blood Health Institute, NIH (Apr. 2022 – Mar. 2026).
• A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Doxycycline to Reduce Progression of Emphysema in HIV, NHLBI (Oct. 2021 – Sept. 2025).
• Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection (PRECISIONS) trial, F. Martinez (PI), Weil Cornell, National Heart Lung Blood Health Institute, NHLBI (Oct. 2019 – Sept. 2025).

Leadership & Service Experience

• Curriculum Committee, TUSP
• Chair, Ph.D. in Regulatory Affairs and Quality Assurance Committee